Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
1 hedge funds and large institutions have $474K invested in Sonnet BioTherapeutics in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
101% more capital invested
Capital invested by funds: $236K → $474K (+$238K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$209K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
1
Perkins Capital Management
Wayzata,
Minnesota
| $210K | +$209K | +1 | New |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $63K | – | – | – |
|
|
IC
3
Intersect Capital
San Ramon,
California
| $38K | – | – | – |
|
4
Dimensional Fund Advisors
Austin,
Texas
| $36K | – | – | – |
|
5
BlackRock
New York
| $33K | – | – | – |
|
|
VF
6
Virtu Financial
New York
| $33K | – | – | – |
|
|
AG
7
Advisor Group
Phoenix,
Arizona
| $26K | – | – | – |
|
8
Bank of America
Charlotte,
North Carolina
| $16K | – | – | – |
|
9
UBS Group
Zurich,
Switzerland
| $9K | – | – | – |
|
|
SCM
10
Stumpf Capital Management
Scottsdale,
Arizona
| $6K | – | – | – |
|
|
QCIG
11
Quad-Cities Investment Group
Davenport,
Iowa
| $4K | – | – | – |
|
|
12
Acadian Asset Management
Boston,
Massachusetts
| – | -$6K | – | – |
|
SONN Hedge Fund Activity: Q2 2018 in Review
1 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2018, worth a combined $474K — up 101% from $236K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SONN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perkins Capital Management, opening a new position worth an estimated $209K. The largest seller was Acadian Asset Management, cutting an estimated $6K.
- 1 institutional investor held Sonnet BioTherapeutics (SONN) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $474K of Sonnet BioTherapeutics stock for Q2 2018, up 101% quarter-over-quarter.
- 1 fund opened new Sonnet BioTherapeutics positions in Q2 2018 and 0 closed out, a net change of +1 holder.
- The largest Sonnet BioTherapeutics buyer in Q2 2018 was Perkins Capital Management, an estimated $209K added.
- The largest Sonnet BioTherapeutics seller in Q2 2018 was Acadian Asset Management, an estimated $6K sold.
Based on aggregated 13F filings for Q2 2018.